Verisante Technology, Inc. (TSX-V: VRS) (OTCQX: VRSEF) is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale. SNNLive spoke with Thomas Braun, CEO of Verisante Technology, Inc. at the Canadian Investor Conference 2014 in Vancouver, BC.
“Verisante technology is a medical device company that makes devices that detect cancer earlier when they’re at their most treatable stage – early detection is a cure for cancer,” begins Mr. Braun. He continues, “What it does is it measures the biochemistry of the tissue in half a second and it tells you whether or not the lesion or the tumor that you’re looking at is benign or malignant.”
Mr. Braun explains, “A study done in Australia on a huge number of patients show that doctors have a sensitivity for melanoma up to about 33%. That means they’re missing about 67% than the ones that they do biopsy, over 80% come back negative.” He adds, “What our device does is it’s telling the doctor which ones to biopsy so that they actually hit the nail on the head.” For more information, check out their website at www.verisante.com....
© 2017 Stock News Now
Supported by Superior Web Solutions